July 2 (Reuters) - Eli Lilly and Co Lly.n:
7月2日(路透社)- 禮來公司Lly.n:
Lilly's Kisunla™ (Donanemab-Azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease
Eli Lilly: Price of Each Vial of Kisunla Is $695.65
Eli Lilly: Coverage & Reimbursement for Kisunla Now Available for Eligible Patients on Medicare
Eli Lilly: Kisunla 6 Months Length of Treatment With 6 30-Minute Infusions to Cost $12,522
Eli Lilly - Kisunla 12 Months Length of Treatment With 13 30-Minute Infusions to Cost $32,000
Eli Lilly: Intends to Donate Kisunla to Lilly Cares Foundation
FDA批准Lilly的Kisunla™ (Donanemab-Azbt)用於治療早期症狀的阿爾茨海默病
伊利蓮每支Kisunla的價格爲695.65美元。
Eli Lilly:Kisunla 的 Medicare 資格患者現在可獲得覆蓋和報銷
Eli Lilly:Kisunla使用6個30分鐘輸注治療6個月,費用爲$12,522。
禮來-基舒尼拉12個月治療帶有13個30分鐘注射的費用爲32,000美元
伊利莎白·禮來公司:打算將Kisunla捐贈給禮來慈善基金會。
Source Text for Eikon: Id:Npn5Yfd56a
Eikon的來源文本:編號:Npn5Yfd56a
Further Company Coverage: Lly.n
進一步的公司新聞報道:Lly.n